Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: present progress and future instructions. Blood Most cancers J. 2021;11:41–66.
Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949–62.
Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M, et al. Immunotherapy in acute myeloid leukemia: the place we stand. Entrance Oncol. 2021;11:656218.
Karlsson L, Cheuk D, De Moerloose B, Hasle H, Jahnukainen Ok, Juul-Dam KL, et al. Traits and end result of main resistant illness in paediatric acute myeloid leukaemia. Br J Haematol. 2023;201:757–65.
Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia impact. Exp Hematol. 2017;48:1–11.
Krieger E, Qayyum R, Keating A, Toor A. Elevated donor inhibitory KIR with identified HLA interactions present safety from relapse following HLA matched unrelated donor HCT for AML. Bone Marrow Transplant. 2021;56:2714–22.
Sweeney C, Vyas P. The graft-versus-leukemia impact in AML. Entrance Oncol. 2019;9:1217.
Forgeard N, Jestin M, Vexiau D, Chevillon F, Ricadat E, Peffault de Latour R, et al. Sexuality- and fertility-related points in ladies after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021;27:432.e1–6.
Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137:471–84.
Koedijk JB, van der Werf I, Calkoen FG, Nierkens S, Kaspers GJL, Zwaan CM, et al. Paving the way in which for immunotherapy in pediatric acute myeloid leukemia: present information and the way in which ahead. Cancers. 2021;13:4364.
Subklewe M, Bücklein V, Sallman D, Daver N. Novel immunotherapies within the remedy of AML: is there hope? Hematol Am Soc Hematol Educ Program. 2023;2023:691–701.
Binnewies M, Roberts EW, Kersten Ok, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for efficient remedy. Nat Med. 2018;24:541–50.
Koedijk JB, van der Werf I, Penter L, Vermeulen MA, Barneh F, Perzolli A, et al. A multidimensional evaluation reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates within the bone marrow of pediatric acute myeloid leukemia. medRxiv. 2023;30:2023.03.03.23286485.
Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, et al. Immunogenomic panorama of hematological malignancies. Most cancers Cell. 2020;38:380–99.e13.
Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137:751–62.
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, security, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, part II research. Most cancers Discov. 2019;9:370–83.
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in most cancers prognosis and therapeutic efficacy. Nat Rev Most cancers. 2020;20:662–80.
Lamble AJ, Lind EF. Focusing on the immune microenvironment in acute myeloid leukemia: a deal with T cell immunity. Entrance Oncol. 2018;8:213.
Vadakekolathu J, Rutella S. Escape from T-cell focusing on immunotherapies in acute myeloid leukemia. Blood. 2023;142:221–37.
Curran E, Corrales L, Kline J. Focusing on the innate immune system as immunotherapy for acute myeloid leukemia. Entrance Oncol. 2015;5:83.
Engblom C, Pfirschke C, Pittet MJ. The function of myeloid cells in most cancers therapies. Nat Rev Most cancers. 2016;16:447–62.
Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and restrict the efficacy of anti-PD-1 remedy. Proc Natl Acad Sci USA. 2018;115:E4041–50.
Miari KE, Guzman ML, Wheadon H, Williams MTS. Macrophages in acute myeloid leukaemia: vital gamers in remedy resistance and affected person outcomes. Entrance Cell Dev Biol. 2021;9:692800.
Al-Matary YS, Botezatu L, Opalka B, Hönes JM, Lams RF, Thivakaran A, et al. Acute myeloid leukemia cells polarize macrophages in direction of a leukemia supporting state in a Development issue independence 1 dependent method. Haematologica. 2016;101:1216–27.
Wu T, Dai Y. Tumor microenvironment and therapeutic response. Most cancers Lett. 2017;387:61–8.
Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot Ok. Flip again the time: focusing on tumor infiltrating myeloid cells to revert most cancers development. Entrance Immunol. 2018;9:1977.
Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates most cancers development. Most cancers Res. 2019;79:4557–66.
Poupot M. Why goal innate immune cells in cancers? Cancers. 2021;13:690.
Park MD, Silvin A, Ginhoux F, Merad M. Macrophages in well being and illness. Cell. 2022;185:4259–79.
Pittet MJ, Michielin O, Migliorini D. Scientific relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19:402–21.
Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, et al. MUC1-mediated induction of myeloid-derived suppressor cells in sufferers with acute myeloid leukemia. Blood. 2017;129:1791–801.
Baragaño Raneros A, Martín-Palanco V, Fernandez AF, Rodriguez RM, Fraga MF, Lopez-Larrea C, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015;16:71–82.
Paczulla AM, Rothfelder Ok, Raffel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572:254–9.
Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, et al. CD200 expression suppresses pure killer cell operate and straight inhibits affected person anti-tumor response in acute myeloid leukemia. Leukemia. 2011;25:792–9.
Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour development. Semin Most cancers Biol. 2008;18:349–55.
Locati M, Curtale G, Mantovani A. Range, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–47.
Laviron M, Petit M, Weber-Delacroix E, Combes AJ, Arkal AR, Barthélémy S, et al. Tumor-associated macrophage heterogeneity is pushed by tissue territories in breast most cancers. Cell Rep. 2022;39:110865.
Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792–809.e23.
Weinhäuser I, Pereira-Martins DA, Almeida LY, Hilberink JR, Silveira DRA, Quek L, et al. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and bettering mitochondrial metabolism. Sci Adv. 2023;9:eadf8522.
Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, et al. Immune profiles in acute myeloid leukemia bone marrow affiliate with affected person age, T-cell receptor clonality, and survival. Blood Adv. 2020;4:274–86.
Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Perumalla P, et al. Single-cell evaluation reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat Commun. 2023;14:6209.
Mussai F, De Santo C, Abu-Dayyeh I, Sales space S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122:749–58.
Chao MP, Takimoto CH, Feng DD, McKenna Ok, Gip P, Liu J, et al. Therapeutic focusing on of the macrophage immune checkpoint CD47 in myeloid malignancies. Entrance Oncol. 2020;9:1380.
Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-clinical improvement of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. 2015;10:e0137345.
Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab mixed with azacitidine in sufferers with beforehand untreated AML: part Ib outcomes. J Clin Oncol. 2023;41:4893–904.
Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to keep away from phagocytosis. Cell. 2009;138:271–85.
Home IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Most cancers Res. 2020;26:487–504.
Hoch T, Schulz D, Eling N, Gómez JM, Levesque MP, Bodenmiller B. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes options of the response to immunotherapy. Sci Immunol. 2022;7:eabk1692.
Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in most cancers pathogenesis. J Immunol. 2015;194:2985–91.
Liu Ok, Nussenzweig MC. Origin and improvement of dendritic cells. Immunol Rev. 2010;234:45–54.
Lucarini V, Melaiu O, Tempora P, D’Amico S, Locatelli F, Fruci D. Dendritic cells: behind the scenes of T-cell infiltration into the tumor microenvironment. Cancers. 2021;13:433.
Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in tumor-associated tertiary lymphoid constructions sign a Th1 cytotoxic immune contexture and license the optimistic prognostic worth of infiltrating CD8+ T cells. Most cancers Res. 2014;74:705–15.
Koucký V, Bouček J, Fialová A. Immunology of plasmacytoid dendritic cells in strong tumors: a short assessment. Cancers. 2019;11:470.
Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-α manufacturing by plasmacytoid dendritic cells favors regulatory T-cell growth that will contribute to breast most cancers development. Most cancers Res. 2012;72:5188–97.
Derolf AR, Laane E, Björklund E, Saft L, Björkholm M, Porwit A. Dendritic cells in bone marrow at analysis and after chemotherapy in grownup sufferers with acute myeloid leukaemia. Scand J Immunol. 2014;80:424–31.
Kline DE, MacNabb BW, Chen X, Chan WC, Fosco D, Kline J. CD8α+ dendritic cells dictate leukemia-specific CD8+ T cell fates. J Immunol. 2018;201:3759–69.
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, et al. Plasmacytoid dendritic cells proliferation related to acute myeloid leukemia: phenotype profile and mutation panorama. Haematologica. 2021;106:3056–66.
Mohty M, Blaise D, Faucher C, Bardou VJ, Gastaut JA, Viens P, et al. Affect of plasmacytoid dendritic cells on end result after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia. 2005;19:1–6.
Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil variety and plasticity in tumour development and remedy. Nat Rev Most cancers. 2020;20:485–503.
Bilen MA, Dutcher GMA, Liu Y, Ravindranathan D, Kissick HT, Carthon BC, et al. Affiliation between pretreatment neutrophil-to-lymphocyte ratio and end result of sufferers with metastatic renal-cell carcinoma handled with nivolumab. Clin Genitourin Most cancers. 2018;16:e563–75.
Shaul ME, Fridlender ZG. Tumour-associated neutrophils in sufferers with most cancers. Nat Rev Clin Oncol. 2019;16:601–20.
Luo Y, Xu Y, Li X, Shi X, Huang P, Chen Y, et al. A prognostic mannequin of seven immune genes to foretell total survival in childhood acute myeloid leukemia. Biomed Res Int. 2022;2022:7724220.
Mushtaq MU, Chaudhary SG, Murthy GSG, Corridor AC, Atallah EL, Mattison RJ. Prognostic significance of neutrophil-to-lymphocyte ratio in relapsed/refractory acute myeloid leukemia. Blood. 2018;132:5246
Mika T, Ladigan S, Schork Ok, Turewicz M, Eisenacher M, Schmiegel W, et al. Monocytes-neutrophils-ratio as predictive marker for failure of first induction remedy in AML. Blood Cells Mol Dis. 2019;77:103–8.
Derakhshani A, Vahidian F, Alihasanzadeh M, Mokhtarzadeh A, Lotfi Nezhad P, Baradaran B. Mast cells: a double-edged sword in most cancers. Immunol Lett. 2019;209:28–35.
Shi S, Ye L, Yu X, Jin Ok, Wu W. Deal with mast cells within the tumor microenvironment: present information and future instructions. Biochim Biophys Acta Rev Most cancers. 2023;1878:188845.
Ribatti D. Mast cells in lymphomas. Crit Rev Oncol Hematol. 2016;101:207–12.
Mao Y, Feng Q, Zheng P, Yang L, Zhu D, Chang W, et al. Low tumor infiltrating mast cell density confers prognostic profit and displays immunoactivation in colorectal most cancers. Int J Most cancers. 2018;143:2271–80.
Taskinen M, Karjalainen-Lindsberg ML, Leppä S. Prognostic affect of tumor-infiltrating mast cells in sufferers with follicular lymphoma handled with rituximab and CHOP. Blood. 2008;111:4664–7.
Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, et al. Tumor-infiltrating mast cells are related to resistance to anti-PD-1 remedy. Nat Commun. 2021;12:346.
Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, et al. Expression of mast cell tryptase by myeloblasts in a gaggle of sufferers with acute myeloid leukemia. Blood. 2001;98:2200–9.
Wang S, Zhao X, Wu S, Cui D, Xu Z. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark Res. 2023;11:34.
Epperly R, Gottschalk S, Velasquez MP. A bump within the street: how the hostile AML microenvironment impacts CAR T cell remedy. Entrance Oncol. 2020;10:262.
Movahedi Ok, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive exercise. Blood. 2008;111:4233–44.
Hyun SY, Na EJ, Jang JE, Chung H, Kim SJ, Kim JS, et al. Immunosuppressive function of CD11b+ CD33+ HLA-DR– myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia. Most cancers Med. 2020;9:7007–17.
Solar H, Li Y, Zhang ZF, Ju Y, Li L, Zhang BC, et al. Enhance in myeloid-derived suppressor cells (MDSCs) related to minimal residual illness (MRD) detection in grownup acute myeloid leukemia. Int J Hematol. 2015;102:579–86.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136:2812–23.
Tohumeken S, Baur R, Böttcher M, Stoll A, Loschinski R, Panagiotidis Ok, et al. Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation by way of TLR2/Akt/mTOR signaling. Most cancers Res. 2020;80:3663–76.
Challagundla KB, Smart PM, Neviani P, Chava H, Murtadha M, Xu T, et al. Exosome-mediated switch of microRNAs throughout the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Most cancers Inst. 2015;107:djv135.
Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, et al. Macrophages derived exosomes ship miR-223 to epithelial ovarian most cancers cells to elicit a chemoresistant phenotype. J Exp Clin Most cancers Res. 2019;38:81.
Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, et al. VISTA is very expressed on MDSCs and mediates an inhibition of T cell response in sufferers with AML. Oncoimmunology. 2018;7:e1469594.
Lengthy AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, et al. Discount of MDSCs with all-trans retinoic acid improves CAR remedy efficacy for sarcomas. Most cancers Immunol Res. 2016;4:869–80.
Regulation AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic goal for most cancers. Cells. 2020;9:561.
Orange JS. Pure killer cell deficiency. J Allergy Clin Immunol. 2013;132:515–25.
Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in most cancers: underlying mechanisms and potential targets for most cancers immunotherapy. Cancers. 2020;12:1760.
Guillaume J, Perzolli A, Boes M. Methods to beat low MHC-I expression in paediatric and grownup tumours. Immunother Adv. 2023;4:ltad028.
Shin MH, Kim J, Lim SA, Kim J, Kim SJ, Lee KM. NK cell-based immunotherapies in most cancers. Immune Netw. 2020;20:e14.
Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, et al. Pure killer cells infiltrating human nonsmall-cell lung most cancers are enriched in CD56 vibrant CD16(-) cells and show an impaired functionality to kill tumor cells. Most cancers. 2008;112:863–75.
Fauriat C, Simply-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, et al. Poor expression of NCR in NK cells from acute myeloid leukemia: evolution throughout leukemia remedy and affect of leukemia cells in NCRdull phenotype induction. Blood. 2007;109:323–30.
Jamal E, Azmy E, Ayed M, Aref S, Eisa N. Scientific affect of proportion of pure killer cells and pure killer-like T cell inhabitants in acute myeloid leukemia. J Hematol. 2020;9:62–70.
Darji A, Desai N, Modi R, Khamar B, Rajkumar S. Institution of cell line with NK/NKT phenotype from myeloid NK cell acute leukemia. Leuk Res. 2017;61:77–83.
Zhigarev D, MacFarlane AW, Drenberg CD, Nejati R, Varshavsky A, Campbell KS. NK cells of acute myeloid leukemia sufferers exhibit exhausted phenotype with impaired useful exercise. Blood. 2021;138:4466.
Costa AFO, Kuznetsova V, Marani LO, Lopes IA, Binelli LS, Scheucher PS, et al. Dysregulated activating and inhibitory receptors on pure killer cells predicts immune escape and poor outcomes in acute myeloid leukemia. Blood. 2022;140:9113–4.
Sandoval-Borrego D, Moreno-Lafont MC, Vazquez-Sanchez EA, Gutierrez-Hoya A, López-Santiago R, Montiel-Cervantes LA, et al. Overexpression of CD158 and NKG2A inhibitory receptors and underexpression of NKG2D and NKp46 Activating receptors on NK cells in acute myeloid leukemia. Arch Med Res. 2016;47:55–64.
Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, et al. CD137 ligand mediates reverse results in human and mouse NK cells and impairs NK-cell reactivity in opposition to human acute myeloid leukemia cells. Blood. 2010;115:3058–69.
Kursunel MA, Esendagli G. A co-inhibitory alliance in myeloid leukemia: TIM-3/Galectin-9 complicated as a brand new goal for checkpoint blockade remedy. EBioMedicine. 2017;23:6–7.
Hattori N, Kawaguchi Y, Sasaki Y, Shimada S, Murai S, Abe M, et al. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 immune checkpoint expression ranges in allogeneic stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 2019;25:861–7.
Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from sufferers with acute myeloid leukemia suppress pure killer cell operate by way of membrane-associated remodeling progress factor-beta1. Haematologica. 2011;96:1302–9.
Stringaris Ok, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, et al. Leukemia-induced phenotypic and useful defects in pure killer cells predict failure to attain remission in acute myeloid leukemia. Haematologica. 2014;99:836–47.
Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, et al. Elevated frequency and suppression by regulatory T cells in sufferers with acute myelogenous leukemia. Clin Most cancers Res. 2009;15:3325–32.
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit pure killer-cell proliferation, cytotoxicity, and cytokine manufacturing: function of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327–33.
Beldi-Ferchiou A, Caillat-Zucman S. Management of NK cell activation by immune checkpoint molecules. Int J Mol Sci. 2017;18:2129.
Liu G, Zhang Q, Yang J, Li X, Xian L, Li W, et al. Elevated TIGIT expressing NK cells with dysfunctional phenotype in AML sufferers correlated with poor prognosis. Most cancers Immunol Immunother. 2022;71:277–87.
Blum WG, Mims AS. Treating acute myeloid leukemia within the trendy period: a primer. Most cancers. 2020;126:4668–77.
Anderson J, Majzner RG, Sondel PM. Immunotherapy of neuroblastoma: details and hopes. Clin Most cancers Res. 2022;28:3196–206.
Bayón-Calderón F, Toribio ML, González-García S. Details and challenges in immunotherapy for T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2020;21:7685.
Xu J, Niu T. Pure killer cell-based immunotherapy for acute myeloid leukemia. J Hematol Oncol. 2020;13:167.
Klingemann H. Are pure killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147.
Vatner RE, Formenti SC. Myeloid-derived cells in tumors: results of radiation. Semin Radiat Oncol. 2015;25:18–27.
Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate most cancers. Most cancers Res. 2013;73:2782–94.
Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson Ok, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast most cancers. Genes Dev. 2011;25:2465–79.
Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, et al. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Most cancers. 2015;15:356.
Jacamo RO, Mu H, Zhang QI, Chachad D, Zhiquiang W, Ma W, et al. Impact of CCL2/CCR2 blockade in acute myeloid leukemia. Blood. 2015;126:1348.
Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles throughout liver damage and restore. J Clin Make investments. 2005;115:56–65.
Burnett SH, Kershen EJ, Zhang J, Zeng L, Straley SC, Kaplan AM, et al. Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J Leukoc Biol. 2004;75:612–23.
Jahchan NS, Mujal AM, Pollack JL, Binnewies M, Sriram V, Reyno L, et al. Tuning the tumor myeloid microenvironment to struggle most cancers. Entrance Immunol. 2019;10:1611.
Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion damage. Proc Natl Acad Sci USA. 2004;101:11791–6.
Baselga J, Tabernero JM. Weekly docetaxel in breast most cancers: making use of medical knowledge to affected person remedy. Oncologist. 2001;6:26–9.
Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Entrance Immunol. 2014;5:461.
Karime C, Wang J, Woodhead G, Mody Ok, Hennemeyer CT, Borad MJ, et al. Tilsotolimod: an investigational artificial toll-like receptor 9 (TLR9) agonist for the remedy of refractory strong tumors and melanoma. Skilled Opin Investig Medication. 2022;31:1–13.
Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive exercise of myeloid-derived suppressor cells. J Immunol. 2012;188:1592–9.
Peng Y, Wang Y, Wang M, Lan J, Chen Y. Therapeutic purposes of toll-like receptors (TLRs) agonists in AML. Clin Transl Oncol. 2022;24:2319–29.
Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, et al. Results of TLR agonists on maturation and performance of 3-day dendritic cells from AML sufferers in full remission. J Transl Med. 2011;9:151.
Liljenfeldt L, Dieterich LC, Dimberg A, Mangsbo SM, Loskog AS. CD40L gene remedy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Most cancers Gene Ther. 2014;21:95–102.
Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 prevents the differentiation of monocytes to dendritic cells however promotes their maturation to macrophages. Eur J Immunol. 1998;28:359–69.
Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, et al. Direct inhibition of human acute myeloid leukemia cell progress by IL-12. Immunol Lett. 2010;133:99–105.
Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the flexibility of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Most cancers Res. 2003;63:2150–7.
Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells inside mouse tumors. J Clin Make investments. 2011;121:4746–57.
Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 quickly alters the useful profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 2007;178:1357–62.
Benekli M, Baumann H, Wetzler M. Focusing on sign transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009;27:4422–32.
Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, et al. Constitutive exercise of sign transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is related to brief disease-free survival. Blood. 2002;99:252–7.
Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123:15–25.
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling within the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314–21.
Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp Ok, Armstrong B, et al. Focusing on Stat3 within the myeloid compartment drastically improves the in vivo antitumor features of adoptively transferred T cells. Most cancers Res. 2010;70:7455–64.
He W, Zhu Y, Mu R, Xu J, Zhang X, Wang C, et al. A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for most cancers immunotherapy. Biochem Pharm. 2017;145:132–46.
Timosenko E, Hadjinicolaou AV, Cerundolo V. Modulation of cancer-specific immune responses by amino acid degrading enzymes. Immunotherapy. 2017;9:83–97.
Manuel ER, Diamond DJ. A street much less traveled paved by IDO silencing: Harnessing the antitumor exercise of neutrophils. Oncoimmunology. 2013;2:e23322.
Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, et al. A novel immunohistochemical rating to foretell early mortality in acute myeloid leukemia sufferers primarily based on indoleamine 2,3 dioxygenase expression. Sci Rep. 2017;7:12892.
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an antagonistic prognostic issue and therapeutic antibody goal on human acute myeloid leukemia stem cells. Cell. 2009;138:286–99.
Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for strong tumours. Nat Rev Immunol. 2023;23:106–20.
Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et al. Rising phagocytosis checkpoints in most cancers immunotherapy. Sign Transduct Goal Ther. 2023;8:104.
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Solar W, et al. CD40 agonists alter tumor stroma and present efficacy in opposition to pancreatic carcinoma in mice and people. Science. 2011;331:1612–6.
Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Make investments. 2013;123:1999–2010.
Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming tumor-associated macrophages by antibody focusing on inhibits most cancers development and metastasis. Cell Rep. 2016;15:2000–11.
Liang S, Cai J, Li Y, Yang R. 1,25-Dihydroxy-Vitamin D3 induces macrophage polarization to M2 by upregulating T-cell Ig-mucin-3 expression. Mol Med Rep. 2019;19:3707–13.
Jiang X, Zhou T, Xiao Y, Yu J, Dou S, Chen G, et al. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. Oncoimmunology. 2016;5:e1211219.
Qian Y, Yang T, Liang H, Deng M. Myeloid checkpoints for most cancers immunotherapy. Chin J Most cancers Res. 2022;34:460–82.
Ruggeri L, Capanni M, Urbani E, Perruccio Ok, Shlomchik WD, Tosti A, et al. Effectiveness of donor pure killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.
Schlegel P, Ditthard Ok, Lang P, Mezger M, Michaelis S, Handgretinger R, et al. NKG2D signaling results in NK cell mediated lysis of childhood AML. J Immunol Res. 2015;2015:473175.
Rubnitz JE, Inaba H, Ribeiro RC, Kilos S, Rooney B, Bell T, et al. NKAML: a pilot research to find out the protection and feasibility of haploidentical pure killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28:955–9.
Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, et al. Donor memory-like NK cells persist and induce remissions in pediatric sufferers with relapsed AML after transplant. Blood. 2022;139:1670–83.
Nguyen R, Wu H, Kilos S, Inaba H, Ribeiro RC, Cullins D, et al. A part II medical trial of adoptive switch of haploidentical pure killer cells for consolidation remedy of pediatric acute myeloid leukemia. J Immunother Most cancers. 2019;7:81.
Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Most cancers Discov. 2020;10:1854–71.
Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like pure killer cells exhibit enhanced responses in opposition to myeloid leukemia. Sci Transl Med. 2016;8:357ra123.
Reusing SB, Vallera DA, Manser AR, Vatrin T, Bhatia S, Felices M, et al. CD16xCD33 bispecific killer cell engager (BiKE) as potential immunotherapeutic in pediatric sufferers with AML and biphenotypic ALL. Most cancers Immunol Immunother. 2021;70:3701–8.
Stein AS, Bajel A, Fleming S, Jongen-Lavrencic M, Garciaz S, Maiti A, et al. An open-label, first-in-human, dose-escalation research of SAR443579 administered as single agent by intravenous infusion in sufferers with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS). Blood. 2022;140:7476–7.
Hofmann S, Schubert M-L, Wang L, He B, Neuber B, Dreger P, et al. Chimeric antigen receptor (CAR) T cell remedy in acute myeloid leukemia (AML). J Clin Med. 2019;8:200.
Gurney M, O’Dwyer M. Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia. Cancers. 2021;13:1568.
Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical pure killer cells is improved utilizing IL-2 diphtheria toxin fusion protein. Blood. 2014;123:3855–63.
Shah NN, Baird Ok, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, et al. Acute GVHD in sufferers receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015;125:784–92.
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, et al. Systemic IL-15 promotes allogeneic cell rejection in sufferers handled with pure killer cell adoptive remedy. Blood. 2022;139:1177–83.
